These stocks made big news on Wednesday despite the market being flat.
Clearwire (CLWR) jumped over 27% after a big insider purchase of stock. The company disclosed in a Form 4 filing the Chairman John Stanton purchased 2.76 million shares on the open market over the last week. His prices of purchases ranged from $1.78 to $1.89. The stock closed at $2.33 on Wednesday.
Claude Resources (NYSEMKT:CGR) rose 16% after it released new exploration results from its new hanging wall discovery at its Seabee Gold Mine. Highlights from the programs include: 8.81 grams of gold per tonne (cut) over 4.9 metres true width (U11-349); 5.33 grams of gold per tonne (cut) over 4.8 metres true width (U11-350); and 6.90 grams of gold per tonne (cut) over 10.0 metres true width (U11-629).
Speaking today in Saskatoon, Philip Ng, Senior Vice President, Mining Operations stated that "We have mobilized two underground drills on the L62 Zone and are looking to add a third drill to explore and define the L62 Zone and other near mine targets. This series of intercepts with above average true widths and economic gold grades are strong indications that we have discovered a new gold-bearing structure. As the L62 zone is located approximately 300 metres from our underground infrastructure on multiple levels, we will likely be in a position to start mining the L62 in the first half of 2012 to expand our existing production profile out of Seabee Mine."
MELA Sciences (MELA) jumped 14% after providing a statement regarding the FDA’s draft guidance on Design Considerations for Pivotal Clinical Investigations for Medical Devices, including those conducted to support Premarket Approval (NYSEARCA:PMA) applications. The draft guidance, which was issued August 15, discusses various recommended study designs, including randomized and blinded clinical studies.
The CEO said "We hold ourselves to the highest, most rigorous clinical standards, and consequently when we designed the pivotal study of MelaFind with the FDA, we insisted on conducting a blinded study in which patients underwent both tests, investigators' eyes and MelaFind, which is more rigorous and scientifically preferred to randomization… From what I understand about the new FDA draft guidance, the protocol we agreed to with FDA years ago meets or exceeds what the agency is now proposing."
The company submitted a PMA application for MelaFind to the FDA over two years ago, yet no final decision has been made.
Progressive Waste Solutions (BIN) rose 7% after it received approval from the Toronto Stock Exchange ("TSX") to repurchase common shares of the company pursuant to a normal course issuer bid ("NCIB").
Under the NCIB, up to 4,000,000 common shares (representing approximately 3.3% of the issued and outstanding common shares) may be repurchased in open market transactions on the TSX, the New York Stock Exchange and/or alternative trading systems between August 19, 2011 and August 18, 2012.
Premier Exhibitions (NASDAQ:PRXI) fell over 5% after providing additional detail on the court’s decision on Monday to give the company the title to the Titanic Artifacts. On Monday, the United States District Court for the Eastern District of Virginia, Norfolk Division, granted title to RMS Titanic ("RMST"), a wholly owned subsidiary of the company, for approximately 3,000 artifacts recovered from the wreck of Titanic during RMST's expeditions conducted in 1993, 1994, 1996, 1998, 2000, and 200
On Wednesday, the company said that the title to the Post 1987 Artifacts comes with certain covenants and conditions drafted and negotiated by the company and the United States government. These covenants and conditions govern the maintenance and future disposition of the artifacts. These covenants and conditions include the following: the approximately 1,800 "1987 Artifacts" and the approximately 3,000 "Post 1987 Artifacts" must be maintained as a single collection; the combined collections can only be sold together, in their entirety, and any buyer would be subject to the same conditions applicable to RMST; and RMST must comply with provisions that guarantee the long-term protection of all of the artifacts.
The covenants and conditions could have an impact on the appraised value of the artifacts and on the alternatives the company has with respect to the assets. However, the company agreed to and fully understands the covenants and conditions, and is evaluating all alternatives to utilize the assets to maximize their value to shareholders.
The company further said that together, the 1987 Artifacts, the Post 1987 Artifacts, and the work product and intellectual property have an appraised value of approximately $189 million. This estimated value of the collection pre-dates the intellectual property acquired from the 2010 expedition and any additional artifacts or intellectual property that may be obtained in the future. The company had a market cap of just under $82 million at the time of this writing providing an upside of more than 100% of the company’s estimate of the value of the artifacts is close to what it says it is.
Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.